Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2025-04-24 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
拟续聘2025年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Tianjian CPA Firm) for the 2025 fiscal year audit services. It details the firm's background, audit fees, and the approval process by the board and audit committee. There is no actual audit report or financial statements included, only information about the appointment process and firm credentials. The document length is 2695 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates to audit services and auditor appointment, but it is not a full audit report or annual report itself. FY 2025
2025-04-24 Chinese
关于拟修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed amendments to the company's Articles of Association (公司章程), specifically changes to registered capital and total shares. It includes details about the board resolution and the need for shareholder approval. There is no financial data, no full report, and the document is relatively short (752 characters). It is not a full Annual Report, Interim Report, or any financial statement. It is a regulatory announcement about governance documents and corporate structure changes, but not a governance report itself. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-04-24 Chinese
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司2024年度募集资金存放与使用情况的专项核查报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the 2024 annual special verification of the deposit and use of raised funds by Zhejiang Haisheng Pharmaceutical Co., Ltd. It includes specific financial figures related to fundraising, usage, bank accounts, investment projects, changes in fund usage, and auditor opinions. The document references regulatory compliance with securities laws and listing rules, and includes an auditor's special verification opinion on the use of raised funds. The content focuses on the management and use of capital raised through a public stock issuance, with detailed financial data and analysis for the fiscal year 2024. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report but a substantive report itself, and it is not a general regulatory filing or a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2025-04-24 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制自我评价报告" which translates to "Internal Control Self-Evaluation Report." It discusses the company's internal control evaluation as of December 31, 2024, covering the effectiveness of internal controls over financial reporting and operational processes. The document includes detailed descriptions of internal control activities, organizational structure, asset management, and risk management. It also states that no significant deficiencies were found in internal controls. This type of document is a standalone report focused on internal control evaluation and audit-related information, not a full annual report or interim financial statement. It is not an announcement or a brief notice but a substantive report on internal control and audit results. Therefore, it fits the category of Audit Report / Information (AR). The document length (6295 characters) supports it being a full report rather than a brief announcement or certification. Hence, the classification is AR with high confidence. FY 2024
2025-04-24 Chinese
2024年审计报告
Audit Report / Information Classification · 100% confidence The document contains an audit report for Zhejiang Haisheng Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2024. It includes detailed audit opinions, basis for the audit, key audit matters such as revenue recognition and fixed assets measurement, responsibilities of management and auditors, and extensive financial statements including balance sheet, income statement, cash flow statement, and notes. The presence of a formal audit opinion and detailed financial statements indicates this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR).
2025-04-24 Chinese
2024年度独立董事述职报告（王兴斌）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the director's duties, attendance at meetings, oversight activities, and opinions on company governance and compliance during the year. It is a narrative report on the director's performance and observations rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. The content aligns with a management or governance-related report focusing on the director's role and activities. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 4079 characters, which is relatively short but contains substantive content about management oversight rather than just an announcement or certification, so it is not RNS or RPA.
2025-04-24 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.